Education | January 12, 2023
Agent Capital’s Associate, Jonathan Ark’s PhD Work Published in Cell
Read More
Press Release | January 11, 2023
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Read More
Press Release | January 9, 2023
Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
Read More
Press Release | January 6, 2023
Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
Read More
